Infection Prevention Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Infection Prevention Devices Market Trends and Insights

Rising Healthcare-Associated Infection Prevention Spending

Underfunded national infection prevention and control systems are converting policy commitments into procurement for validated infrastructure. The World Health Organization reported that 71% of countries had an active infection prevention and control program, but only 6% met all minimum requirements in 2023-2024^{[1]World Health Organization, “Global Report on Infection Prevention and Control 2024,” World Health Organization, who.int.}. Its 2024-2030 action plan seeks to raise the share of countries meeting those requirements above 90% by 2030. Patients in low- and middle-income countries faced up to 20 times the healthcare-associated infection risk seen in high-income countries. This gap directs funding toward categories that offer documented audit results, including sterilization monitoring, biological indicators, and assurance consumables. The infection prevention devices market can therefore benefit as national programs in Southeast Asia and Sub-Saharan Africa move from policy adoption toward facility-level implementation. These procurement cycles can widen the addressable base for the infection prevention devices market.

Increasing Surgical and Interventional Procedure Volumes

Higher procedure volumes raise sterilization throughput needs within facilities and increase demand for reprocessing equipment, consumables, and monitoring devices. Outpatient care has moved more surgical activity into smaller settings that require dependable sterile processing capacity. Many ambulatory surgery centers have fewer than 3 operating rooms and do not maintain dedicated sterile processing staff. This setting favors compact and automated infection prevention devices that require limited operator training. A concentrated range of procedures can also make procedure-specific sterilization specifications more important in purchasing decisions. The infection prevention devices market has an opportunity where providers need standardized equipment and service support across distributed sites. This setting places ease of operation at the center of the purchasing of infection prevention devices.

Expansion of Low-Temperature Sterilization for Heat-Sensitive Devices

Complex multi-lumen instruments, flexible robotic components, and reusable endoscopes cannot always tolerate conventional steam cycles. Vaporized hydrogen peroxide sterilization operates at reduced pressure and can provide validated sterilization without the moisture or heat damage associated with saturated steam. FDA guidance and EU Medical Device Regulation requirements have made validation more important for thermolabile devices. ISO 11138 biological indicator protocols raise validation requirements but also strengthen the position of suppliers with certified systems. Hospitals that install these systems also need compatible monitoring consumables and validation software. This bundled need supports vertically integrated suppliers in the infection prevention devices market, where certified equipment, monitoring supplies, and validation software are increasingly considered together.

Digitization of Sterilization Assurance and Instrument Tracking

Digital tracking makes sterilization documentation more visible and easier to audit at high-volume facilities. The main requirement is liability management because incomplete instrument-level records can expose facilities to accreditation findings and contractual pressure. Getinge launched the Aquadis Endo 110 in June 2026 with RFID integrated into each reprocessing cycle and connections to FleetView and T-DOC Endo platforms. The system illustrates how workflow information can be connected to equipment rather than handled as a separate administrative process in the infection prevention devices market. Interoperable data links can make compliance visible at the patient episode level. This raises the competitive threshold for suppliers offering stand-alone analog products in the infection prevention devices market, especially where facilities require auditable cycle records across connected workflows.

Ethylene Oxide Emission Controls and Sterilization Capacity Risk

Ethylene oxide is an essential sterilization method for medical devices, but it is also classified as a carcinogen. The EPA finalized amendments in April 2024 that required more than 90% reductions in ethylene oxide emissions at commercial sterilization facilities^{[2]U.S. Environmental Protection Agency, “Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxide Commercial Sterilizers,” U.S. Environmental Protection Agency, epa.gov.}. The agency stated that the action addressed facilities that sterilize roughly 50% of U.S. medical devices, or 20 billion devices annually. In March 2026, the EPA proposed reconsidering the 2024 commercial sterilizer rule on medical supply-chain grounds. This uncertainty complicates investment planning for sterilization operators and alternative technology developers. It can promote low-temperature alternatives while limiting new capacity for a method that has no complete substitute for many complex multi-lumen devices.

High Capital and Lifecycle Costs of Advanced Systems

Fully automated low-temperature systems and digital assurance suites require more than an initial equipment purchase. Facilities also fund installation, operational, and performance qualification studies, staff training, service agreements, chemical indicators, biological indicators, and single-use cassettes. These costs accumulate across a 7-to-10-year lifecycle and create a difficult case when procedure volumes are unstable. The constraint is strongest in MEA, parts of South America, and rural Southeast Asia, where healthcare financing and long-term contracting can be limited. Pay-per-cycle and outcome-based service models address some budget concerns, but their use remains constrained where reimbursement and operating budgets are uncertain. This can direct the infection prevention devices market toward lower-cost chemical disinfectants and protective barriers instead of capital-intensive sterilization systems in the fastest-growing geographies. It also shapes the product mix pursued within the infection prevention devices market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Endoscope Reprocessing Supports Faster Growth

Endoscope Reprocessing Devices are projected to grow at a 9.15% CAGR through 2031, ahead of the 6.25% overall forecast. Sterilization Equipment held 38.31% of revenue share in 2025 and remains the largest revenue category. Its broad role spans hospital central sterile supply departments, pharmaceutical manufacturing facilities, and ambulatory care settings. Disinfection Devices support environmental hygiene in intensive care units, isolation rooms, and procedure suites. Sterilization Monitoring and Assurance Devices are becoming more important as providers formalize every-load monitoring under accreditation and audit requirements.

Protective Infection-Prevention Devices provide staff protection, while Medical Waste and Containment Devices support biohazard management. Standards including ISO 374 and EN 374 establish requirements for protective barrier performance. Endoscopy units are processing the same scope fleets more often as procedure backlogs continue, which makes throughput a central purchasing requirement. Getinge's Aquadis Endo 110 delivers 36% higher throughput than its predecessor and a 20-minute standard cycle. The system also provides RFID-enabled traceability through its FleetView and T-DOC Endo connections. Advanced Sterilization Products acquired UVSmart, bringing endoscope high-level disinfection closer to environmental photonic disinfection within a single portfolio^{[3]Advanced Sterilization Products, “ASP + UVSmart: A New Era in UV Disinfection,” Advanced Sterilization Products, asp.com.}.

By Technology: Heat Sterilization Remains Established, Low-Temperature Systems Gain Ground

Heat and High-Temperature Sterilization accounted for 45.24% of revenue share in 2025. It remains established in central sterile supply departments because stainless-steel surgical instruments continue to make up much of the surgical kit inventory. Low-Temperature Sterilization is forecast to record an 8.22% CAGR through 2031 as thermolabile instruments become more common in robotic surgery, minimally invasive procedures, and flexible endoscopy. Radiation Sterilization, including gamma and electron beam methods, remains important for contract sterilization of single-use devices. Chemical Sterilization and Disinfection includes peracetic acid and liquid chemistries used in endoscope reprocessing and environmental cleaning.

X-ray radiation processing is gaining attention as a more precise alternative to ethylene oxide for some applications. STERIS Applied Sterilization Technologies completed an expansion of its X-ray radiation processing facility in Höchstadt, Germany, in July 2026, increasing regional processing capacity for medical device manufacturers. UV-C and photonic disinfection are smaller technologies that are moving from supplementary use toward more central roles in selected clinical settings. A phase II trial conducted from November 2024 to April 2025 in 12 long-term care facilities in Denmark reported 10.4 hospital-treated infections per 10,000 resident-days in far-UVC common rooms, compared with 86.2 under standard care. The adjusted incidence rate ratio was 0.12, with a 95% confidence interval of 0.04-0.34. Developing compliance frameworks and the need for clinical validation make early regulatory clarity important for suppliers in this part of the infection prevention devices market, where equipment performance must be matched with practical adoption requirements.

By Use Case: Healthcare-Associated Infection Prevention Holds the Largest Position

Healthcare-Associated Infection Prevention represented 42.14% of revenue in 2025. The use case is supported by institutional liability related to healthcare-associated infections and quality reporting systems that can penalize facilities for higher infection rates. The World Health Organization identifies healthcare-associated infections as the most frequent adverse events in healthcare delivery worldwide. Respiratory Infection Control is projected to grow at a 7.42% CAGR through 2031. Spending in this area includes ventilator-associated pneumonia prevention, UV-C air disinfection in respiratory isolation units, and stronger respiratory hygiene procedures.

Surgical Site Infection Prevention is tied to established specifications for skin antisepsis, surgical barrier drapes, and air filtration. Endoscope-Associated Infection Prevention is receiving more attention after outbreak investigations associated with inadequately reprocessed complex-channel scopes. Environmental and Surface Hygiene includes UV-C robotic disinfection and EPA-registered surface disinfectants used during terminal cleaning. Better respiratory hygiene can also reduce antibiotic use, which links infection prevention to antimicrobial stewardship objectives. In the Danish far-UVC trial, antibiotic prescriptions in the treated group were 48% lower than under standard care. The adjusted incidence rate ratio for those prescriptions was 0.52, with a 95% confidence interval of 0.29-0.96.

By End User: Hospitals Lead While Diagnostic Laboratories Expand Faster

Hospitals and Clinics accounted for 52.54% of end-user revenue in 2025. They are the main deployment setting for central sterile supply departments, endoscope reprocessing units, and air filtration systems across many infection risk settings. Ambulatory surgery centers require a different approach because they often need smaller equipment footprints and service-bundled models. Their staff may also require interfaces designed for non-specialist operation. Long-Term Care Facilities are expanding as infection risks in residential care settings attract greater regulatory attention. Pharmaceutical and Medical Device Manufacturers remain exposed to ethylene oxide rule changes because they rely on contract sterilization for production validation.

Diagnostic Centers and Clinical Laboratories are projected to grow at an 8.12% CAGR through 2031. Growth in molecular diagnostics, histopathology, and point-of-care testing creates continuing instrument reprocessing needs. Many laboratories are moving from basic chemical disinfection to validated low-temperature or UV-C systems under accreditation and quality management requirements. Laboratory instruments can undergo reprocessing many times each day, which can raise consumable demand per instrument. Suppliers can address this need with compact systems, frequent cycle capability, and fewer operator steps. This creates a clearer growth opportunity for the infection prevention devices industry and the infection prevention devices market among laboratories that previously bought these devices on an opportunistic basis.

Geography Analysis

North America held 36.61% of the revenue share in 2025. Device reprocessing validation standards, healthcare-associated infection reporting requirements, and Joint Commission accreditation obligations support the United States. These requirements make procurement difficult to defer when facilities need documented compliance. Canada aligns closely with comparable sterilization expectations through provincial health authorities. Mexico is reinforcing infection prevention requirements as hospital capacity expands under national healthcare access programs.

Asia-Pacific is projected to grow at a 7.45% CAGR through 2031. China’s hospital construction and renovation commitments, and India’s Ayushman Bharat digital health infrastructure program, are extending secondary and tertiary care access. A 10-year study published in 2026 at a major healthcare institution in Southwestern China found declining healthcare-associated infection rates while antimicrobial use stabilized. The finding supports the value of sustained institution-wide infection prevention investment. It also supports the continued adoption of validated systems in the infection prevention devices market. Japan’s hospital accreditation framework supports replacement cycles for sterilization and reprocessing equipment. South Korea and Australia also contribute through mature private hospital sectors with stringent infection control requirements.

MEA and South America remain smaller contributors but can grow faster as hospital construction and quality improvement programs continue. GCC countries are investing in hospital infrastructure under Vision 2030 and related diversification programs. Their higher-income base can support advanced low-temperature sterilization systems that remain less accessible in other MEA countries. South Africa and the wider Sub-Saharan Africa region represent a longer-term opportunity as World Health Organization program rollout and development funding support structured procurement. Brazil is modernizing public hospital infection control infrastructure, while Argentina’s private hospital sector is upgrading sterilization capacity. The infection prevention devices market size in these regions remains smaller, but their growth can become more relevant to the infection prevention devices market later in the forecast period.